Want to see HOCPY full AI Analyst Report?
Top Page
HOYA
(OTC:HOCPY)
Select Model
Select Model
Rating:74Outperform
Price Target:
$161.00
▲(4.85% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by very strong financial performance (high profitability, conservative balance sheet, solid cash generation). This is tempered by mixed technical signals (improving short-term trend but weaker longer-term trend and negative MACD) and a relatively high P/E with only a modest dividend yield.
Positive Factors
High and resilient profitability
HOYA’s consistently strong gross, operating, and net margins indicate differentiated products and effective execution across its businesses. Durable profitability provides internal funding for innovation, supports resilience through demand cycles, and gives the company room to protect returns while pursuing growth.
Negative Factors
Uneven revenue growth
The upward revenue trend is encouraging, but the uneven pace makes future growth less predictable than the company’s profitability profile. A rebound after weak annual growth may not establish a durable acceleration, requiring continued product innovation and execution to sustain expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
High and resilient profitability
HOYA’s consistently strong gross, operating, and net margins indicate differentiated products and effective execution across its businesses. Durable profitability provides internal funding for innovation, supports resilience through demand cycles, and gives the company room to protect returns while pursuing growth.
Read all positive factors
HOYA (HOCPY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$47.86B
Dividend Yield0.98%
Average Volume (3M)8.59K
Price to Earnings (P/E)28.5
Beta (1Y)0.78
Revenue Growth9.10%
EPS Growth27.89%
CountryUS
Employees37,752
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)803.58
Shares Outstanding334,838,000
10 Day Avg. Volume4,658
30 Day Avg. Volume8,593
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)9.09
Price to Sales (P/S)9.27
P/FCF Ratio39.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.22
Revenue Forecast (FY)$6.59B
HOYA Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1941, HOYA Corporation operates as a global med-tech enterprise and a leading provider of advanced technological and medical solutions. Its extensive "life care" division offers a diverse portfolio, ranging from oph...
How the Company Makes Money
HOYA makes money primarily by selling products and solutions across its major business lines, with revenue generally generated through a mix of high-volume consumables and higher-value equipment.
1) Vision Care (eyeglass lenses): HOYA generates r...
HOYA Financial Statement Overview
Summary
Income Statement
90
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
87
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 999.52B | 1.00T | 885.82B | 762.61B | 734.10B | 670.33B |
| Gross Profit | 788.61B | 793.79B | 766.25B | 421.69B | 631.86B | 567.28B |
| EBITDA | 407.55B | 359.07B | 310.00B | 285.70B | 259.78B | 243.96B |
| Net Income | 271.52B | 268.35B | 202.10B | 181.38B | 168.64B | 164.51B |
Balance Sheet | ||||||
| Total Assets | 1.29T | 1.31T | 1.23T | 1.20T | 1.03T | 992.84B |
| Cash, Cash Equivalents and Short-Term Investments | 551.83B | 576.58B | 538.53B | 525.16B | 426.27B | 426.63B |
| Total Debt | 45.09B | 42.42B | 37.28B | 29.24B | 24.58B | 21.60B |
| Total Liabilities | 269.43B | 267.05B | 262.65B | 241.36B | 213.72B | 203.78B |
| Stockholders Equity | 1.01T | 1.02T | 974.02B | 967.76B | 818.32B | 803.85B |
Cash Flow | ||||||
| Free Cash Flow | 239.53B | 235.25B | 187.19B | 181.73B | 168.36B | 161.18B |
| Operating Cash Flow | 294.56B | 295.24B | 235.11B | 222.80B | 201.83B | 190.06B |
| Investing Cash Flow | -2.94B | -8.04B | -33.19B | -35.81B | -47.50B | -29.30B |
| Financing Cash Flow | -317.04B | -277.01B | -190.35B | -110.89B | -194.59B | -106.72B |
HOYA Technical Analysis
Negative
153.56
Price Trends
155.38
Negative
161.56
Negative
165.27
Negative
Market Momentum
-3.78
Positive
31.42
Neutral
5.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Negative. The current price of 153.56 is above the 20-day moving average (MA) of 151.58, below the 50-day MA of 155.38, and below the 200-day MA of 165.27, indicating a bearish trend. The MACD of -3.78 indicates Positive momentum. The RSI at 31.42 is Neutral, neither overbought nor oversold. The STOCH value of 5.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOCPY.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $135.05B | 43.34 | 17.83% | ― | 20.66% | 21.06% | |
74 Outperform | $47.86B | 28.51 | 26.25% | 0.98% | 9.10% | 27.89% | |
65 Neutral | $49.53B | 54.63 | 3.79% | 2.19% | -2.56% | -40.38% | |
63 Neutral | $6.10B | -35.07 | -2.67% | ― | 8.85% | 37.70% | |
56 Neutral | $1.12B | 265.50 | 1.08% | ― | 51.30% | ― | |
54 Neutral | $10.38B | 18.35 | 6.88% | 0.02% | 4.73% | 43.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HOCPY
HOYA
143.59
4.97
3.59%
BDX
Becton Dickinson
180.94
37.54
26.18%
COO
Cooper Co
55.29
-12.88
-18.89%
ISRG
Intuitive Surgical
393.33
-45.39
-10.35%
STAA
Staar Surgical
20.82
-6.42
-23.57%
BLCO
Bausch + Lomb Corporation
16.85
1.66
10.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.